Goodwin: Myrobalan Therapeutics Receives $400,000 Grant From the Amyotrophic Lateral Sclerosis Association to Advance Its CSF1R Inhibitor Program
February 28, 2024
February 28, 2024
BOSTON, Massachusetts, Feb. 28 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Myrobalan Therapeutics in connection with its $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor-1 receptor (CSF1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS). The grant has been made through the ALS Association's Lawrence and Isabel Barnett Drug Development Program, supplementing the pr . . .
The Life Sciences team advised Myrobalan Therapeutics in connection with its $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor-1 receptor (CSF1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS). The grant has been made through the ALS Association's Lawrence and Isabel Barnett Drug Development Program, supplementing the pr . . .